Management guidance · Q1 FY27 call
Leading Pharmaceuticals & Biotechnology companies on guidance
Sign up free to see every company in the sector ranking and track Sai Parenteral's.
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Sai Parenteral's
Quarter-by-quarter operating performance
| Dec 2025 | Mar 2026 | |
|---|---|---|
| Sales + | 96 | 198 |
| Expenses + | 100 | 172 |
| Operating Profit | -4 | 26 |
| OPM % | -4% | 13% |
| Other Income + | 3 | 3 |
| Interest | 5 | 8 |
| Depreciation | 6 | 8 |
| Profit before tax | -12 | 12 |
| Tax % | -43% | -6% |
| Net Profit + | -7 | 13 |
| EPS in Rs | -1.80 | 2.98 |
Financials of Sai Parenteral's
Annual income statement trend
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales + | 97 | 154 | 163 | 381 |
| Expenses + | 78 | 122 | 124 | 342 |
| Operating Profit | 19 | 32 | 39 | 39 |
| OPM % | 19% | 21% | 24% | 10% |
| Other Income + | 0 | 1 | 1 | 9 |
| Interest | 6 | 11 | 12 | 18 |
| Depreciation | 6 | 9 | 8 | 17 |
| Profit before tax | 7 | 13 | 20 | 12 |
| Tax % | 40% | 33% | 28% | -20% |
| Net Profit + | 4 | 8 | 14 | 14 |
| EPS in Rs | 6.13 | 6.36 | 5.43 | 3.23 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
Financials of Sai Parenteral's
Capital structure and asset base
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 7 | 13 | 13 | 22 |
| Reserves | 24 | 61 | 80 | 469 |
| Borrowings + | 69 | 119 | 94 | 333 |
| Other Liabilities + | 34 | 75 | 85 | 600 |
| Total Liabilities | 134 | 268 | 272 | 1,424 |
| Fixed Assets + | 44 | 70 | 53 | 364 |
| CWIP | 2 | 0 | 0 | 212 |
| Investments | 0 | 0 | 0 | 0 |
| Other Assets + | 88 | 198 | 219 | 848 |
| Total Assets | 134 | 268 | 272 | 1,424 |
Financials of Sai Parenteral's
Operating, investing and financing cash movement
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from Operating Activity + | -13 | -30 | 33 | 93 |
| Cash from Investing Activity + | -19 | -46 | 0 | -274 |
| Cash from Financing Activity + | 24 | 79 | -36 | 596 |
| Net Cash Flow | -8 | 2 | -2 | 415 |
| Free Cash Flow | -30 | -72 | 41 | -184 |
| CFO/OP | -54% | -94% | 86% | 253% |
Financials of Sai Parenteral's
Working capital efficiency and return ratios
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 231 | 302 | 283 | 173 |
| Inventory Days | 83 | 143 | 199 | 259 |
| Days Payable | 140 | 203 | 225 | 224 |
| Cash Conversion Cycle | 174 | 242 | 256 | 208 |
| Working Capital Days | 19 | 72 | 79 | -161 |
| ROCE % | 16% | 17% | 6% |
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.